Our research found that ARL4C orchestrates migration and drug resistance via the RAC1-EMT axis, uncovering a pivotal mechanism underlying treatment-refractory CRC and providing a theoretical basis for combined anti-metastatic and anti-resistance strategies. The gene discussed is RAC1; the disease is colorectal carcinoma.